Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

Marcé, Sílvia; Xicoy, Blanca; García, Olga; Cabezón, Marta; Estrada, Natalia; Vélez, Patricia; Boqué, Concepción; Sagüés, Miguel; Angona, Anna; Teruel Montoya, Raúl; Ferrer Marín, Francisca; Amat, Paula; Hernández Boluda, Juan; Ibarra, Mariana; Anguita Mandly, Eduardo Luis; Cortés, Montserrat; Fernández Ruiz, Andrés; Fontanals, Sandra; Zamora, Lurdes

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of thi...

Descripción completa

Detalles Bibliográficos
Autores:	Marcé, Sílvia, Xicoy, Blanca, García, Olga, Cabezón, Marta, Estrada, Natalia, Vélez, Patricia, Boqué, Concepción, Sagüés, Miguel, Angona, Anna, Teruel Montoya, Raúl, Ferrer Marín, Francisca, Amat, Paula, Hernández Boluda, Juan, Ibarra, Mariana, Anguita Mandly, Eduardo Luis, Cortés, Montserrat, Fernández Ruiz, Andrés, Fontanals, Sandra, Zamora, Lurdes
Tipo de recurso:	artículo
Fecha de publicación:	2021
País:	España
Institución:	Universidad Complutense de Madrid (UCM)
Repositorio:	Docta Complutense
Idioma:	inglés
OAI Identifier:	oai:docta.ucm.es:20.500.14352/4786
Acceso en línea:	https://hdl.handle.net/20.500.14352/4786
Access Level:	acceso abierto
Palabra clave:	Chronic myeloid leukemia BCR-ABL1 transcripts Response to imatinib Survival Discontinuation Relapse-free survival Hematología Oncología 3205.04 Hematología 3201.01 Oncología

id	ES_7b7faafd5a1176b45d8ef3e86feee206
oai_identifier_str	oai:docta.ucm.es:20.500.14352/4786
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with ImatinibMarcé, SílviaXicoy, BlancaGarcía, OlgaCabezón, MartaEstrada, NataliaVélez, PatriciaBoqué, ConcepciónSagüés, MiguelAngona, AnnaTeruel Montoya, RaúlFerrer Marín, FranciscaAmat, PaulaHernández Boluda, JuanIbarra, MarianaAnguita Mandly, Eduardo LuisCortés, MontserratFernández Ruiz, AndrésFontanals, SandraZamora, LurdesChronic myeloid leukemiaBCR-ABL1 transcriptsResponse to imatinibSurvivalDiscontinuationRelapse-free survivalHematologíaOncología3205.04 Hematología3201.01 OncologíaThe most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics, cumulative cytogenetic and molecular responses to IM, acquisition of deep molecular response (DMR) and its duration (sDMR), progression rate (CIP), overall survival (OS), and treatment-free remission (TFR) rate. We studied 202 CML patients, 76 expressing the e13a2 and 126 the e14a2, and correlated the differential transcript expression with the above-mentioned parameters. There were no differences in the cumulative incidence of cytogenetic responses nor in the acquisition of DMR and sDMR between the two groups, but the e14a2 transcript had a positive impact on molecular response during the first 6 months, whereas the e13a2 was associated with improved long-term OS. No correlation was observed between the transcript type and TFR rate.MPDIUniversidad Complutense de Madrid20212021-07-1620212021-07-16journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.14352/4786reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución 3.0 Españahttps://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/47862026-06-02T12:44:21Z
dc.title.none.fl_str_mv	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
title	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
spellingShingle	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib Marcé, Sílvia Chronic myeloid leukemia BCR-ABL1 transcripts Response to imatinib Survival Discontinuation Relapse-free survival Hematología Oncología 3205.04 Hematología 3201.01 Oncología
title_short	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
title_full	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
title_fullStr	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
title_full_unstemmed	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
title_sort	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
dc.creator.none.fl_str_mv	Marcé, Sílvia Xicoy, Blanca García, Olga Cabezón, Marta Estrada, Natalia Vélez, Patricia Boqué, Concepción Sagüés, Miguel Angona, Anna Teruel Montoya, Raúl Ferrer Marín, Francisca Amat, Paula Hernández Boluda, Juan Ibarra, Mariana Anguita Mandly, Eduardo Luis Cortés, Montserrat Fernández Ruiz, Andrés Fontanals, Sandra Zamora, Lurdes
author	Marcé, Sílvia
author_facet	Marcé, Sílvia Xicoy, Blanca García, Olga Cabezón, Marta Estrada, Natalia Vélez, Patricia Boqué, Concepción Sagüés, Miguel Angona, Anna Teruel Montoya, Raúl Ferrer Marín, Francisca Amat, Paula Hernández Boluda, Juan Ibarra, Mariana Anguita Mandly, Eduardo Luis Cortés, Montserrat Fernández Ruiz, Andrés Fontanals, Sandra Zamora, Lurdes
author_role	author
author2	Xicoy, Blanca García, Olga Cabezón, Marta Estrada, Natalia Vélez, Patricia Boqué, Concepción Sagüés, Miguel Angona, Anna Teruel Montoya, Raúl Ferrer Marín, Francisca Amat, Paula Hernández Boluda, Juan Ibarra, Mariana Anguita Mandly, Eduardo Luis Cortés, Montserrat Fernández Ruiz, Andrés Fontanals, Sandra Zamora, Lurdes
author2_role	author author author author author author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv	Universidad Complutense de Madrid
dc.subject.none.fl_str_mv	Chronic myeloid leukemia BCR-ABL1 transcripts Response to imatinib Survival Discontinuation Relapse-free survival Hematología Oncología 3205.04 Hematología 3201.01 Oncología
topic	Chronic myeloid leukemia BCR-ABL1 transcripts Response to imatinib Survival Discontinuation Relapse-free survival Hematología Oncología 3205.04 Hematología 3201.01 Oncología
description	The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics, cumulative cytogenetic and molecular responses to IM, acquisition of deep molecular response (DMR) and its duration (sDMR), progression rate (CIP), overall survival (OS), and treatment-free remission (TFR) rate. We studied 202 CML patients, 76 expressing the e13a2 and 126 the e14a2, and correlated the differential transcript expression with the above-mentioned parameters. There were no differences in the cumulative incidence of cytogenetic responses nor in the acquisition of DMR and sDMR between the two groups, but the e14a2 transcript had a positive impact on molecular response during the first 6 months, whereas the e13a2 was associated with improved long-term OS. No correlation was observed between the transcript type and TFR rate.
publishDate	2021
dc.date.none.fl_str_mv	2021 2021-07-16 2021 2021-07-16
dc.type.none.fl_str_mv	journal article http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://hdl.handle.net/20.500.14352/4786
url	https://hdl.handle.net/20.500.14352/4786
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 Atribución 3.0 España https://creativecommons.org/licenses/by/3.0/es/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 Atribución 3.0 España https://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	MPDI
publisher.none.fl_str_mv	MPDI
dc.source.none.fl_str_mv	reponame:Docta Complutense instname:Universidad Complutense de Madrid (UCM)
instname_str	Universidad Complutense de Madrid (UCM)
reponame_str	Docta Complutense
collection	Docta Complutense
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869411519597379584
score	15,300719

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

Similares en LA Referencia